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Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs) are characterized by clonal hematopoiesis derived from 
a mutated hematopoietic stem cell. Ph-neg MPNs rarely transforms into acute leukemia, and in most cases, the transformation leads 
to the development of acute myeloid leukemia (AML). The incidence of mixed-phenotype leukemia (MPAL) or acute lymphoblastic 
leukemia (ALL) with lineage switch is much rarer. The unidentified lineage of blast cells is due to the immaturity of their undifferentiated 
progenitors with co-expression of myeloid and lymphoid antigens. The prognosis of secondary acute leukemia transformed from 
Ph-neg MPN is very unfavorable, especially in MPAL or lineage switch from ALL to AML cases. Moreover, there are no therapeutic protocols 
for these specific leukemia subtypes. Therefore, we believe that all cases of MPAL or lineage switch leukemia should be reported. This 
article presents the case of a patient with JAK2-positive essential thrombocythemia (ET) transformed to MPAL, and a patient with 
triple-negative primary myelofibrosis (PMF) (negative for JAK2, CALR, and MPL) transformed to ALL with subsequent lineage switch to AML.
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Introduction
Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPNs) 
are characterized by a clonal proliferation of one or more bone marrow 
cell lineages. MPN arises from the mutation in hematopoietic stem cells 
resulting in impaired cytokines expression and dysregulation of kinase 
signaling [1]. Ph-neg MPNs include essential thrombocythemia (ET), 
polycythemia vera (PV), and primary myelofibrosis (PMF).
The transformation of Ph-neg MPNs into acute leukemia is not very 
common with varying incidence depending on the Ph-neg MPN subtype. 
In PMF, the transformation is observed in 20% of patients, while in PV 
and ET, it is observed in 4% and 1% of patients, respectively [2, 3]. 
Most commonly, Ph-neg MPN transforms into acute myeloid leukemia 
(AML). However, there are few reports of transformation into acute 
lymphoblastic leukemia (ALL) (more than 10 cases published) (Tab. I). 
However, no reports on the transformation of Ph-neg MPN to mixed- 
-phenotype acute leukemia (MPAL) and lineage switch from ALL to 
AML were published.
MPAL is a specific type of leukemia in which blasts co-express antigens 
from more than one cell lineage [2] can be difficult to diagnose. 
MPAL diagnostics is based on the guidelines of European Group for 
Immunological Classification of Leukemia (EGIL) [3] and the WHO 
2016 classification of myeloid neoplasms and acute leukemia [4]. 
Leukemias with lineage switch observed during therapy should be 
considered as a separate group [5].
The incidence of MPAL is very low and accounts for approximately 
2–5% of all acute leukemias [2]. Lineage switch from ALL to AML is 
also rare and accounts for approximately 6–9% of relapsed ALL [6, 7]. 
According to the literature, these leukemias are usually treatment- 
-resistant. However, currently, there are no prospective controlled 
clinical trials to determine the optimal treatment protocol [5].
This article describes the case of MPAL in a patient with JAK2-positive 
ET and ALL with lineage switch to AML in a patient with triple-negative 
PMF (for Janus kinase 2 (JAK2), calreticulin (CALR), myeloproliferative 
leukemia virus oncogene (MPL) mutations).
Case report 1
A 53-year-old female, without significant medical history, has 
been referred to a hematology outpatient clinic in March 2010 
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due to thrombocytosis (1.5 G/L). After the exclusion of reactive 
thrombocytosis and myelodysplastic-myeloproliferative neoplasm 
with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) [4], the 
patient was diagnosed with JAK2(V617)-positive ET.
Over the next 4 years, until July 2014, the patient was treated 
with hydroxyurea (HU) with good effect: platelet count (PLT) fell to 
500–600 G/L. In August 2014, anemia (hemoglobin (Hgb) – 9.2 g/dL) 
and thrombocytopenia (PLT – 50 G/L) with normal leukocyte 
count (8.06 G/L) were observed. Physical examination revealed 
hepatosplenomegaly. The following biochemical parameters were 
increased: lactate dehydrogenase (LDH) – 420 U/L, C reactive 
protein (CRP) – 76.1 mg/L, and GGTP 110 U/L. In a myelogram, 
bone marrow was infiltrated with blast cells (53% of all cells 
examined). This population had a mixed phenotype: myelo- and 
T-cell lymphoblastic: CD34+CD13+CD7+cyCD3+CD36+CD33brig
ht+HLA-DR+CD4+CD8-CD5-CD2-CD117-MPO+TdT-CD64-CD71+ 
(Fig.1).The cytochemical profile was nonspecific. As expected 
for lymphoblasts, negative peroxidase and lipid reactions were 
observed. Dispersed, nonspecific esterase staining pattern, typical 
for myeloblasts, was detected. The strong enzymatic activity of acid 
phosphatase has distinguished the population of T-cell lymphoblasts. 
Patient’s karyotype was hyperploid, complex, with i(21q) duplication 
that can be expected both in AML and ALL(57,XX,+1,+2,+2,+dic(6;12)
( q 2 7 ; p 1 3 ) , + d e r ( 8 ) t ( 8 ; 11 ) ( p 11 . 2 ; q 1 3 ) , + d e r ( 9 ) t ( 9 ; 1 6 )
(q13;q13),+11,+add(18)(p11.2),+19,+20,+i(21)(q10)x2[17]/46,XX[3]). 
No BCR-ABL fusion gene was found in FISH using locus-specific 
probes.
Chemotherapy, according to the PALG ALL6 Ph(-) protocol for patients 
>55 years of age (dexamethasone, vincristine, daunorubicin, and peg-
asparaginase), was started in September 2014. Prophylactic central 
nervous system (CNS)-directed treatment was also implemented. 
The chemotherapy was complicated with pancytopenia. The follow-up 
abdominal ultrasound scan from October showed progression of 
hepatosplenomegaly. The myelogram performed on October 14, 2014, 
revealed 2.0% of myeloblasts and 11.0% of mature lymphocytes. 
In cytometry, 2.0% of blasts and positive minimal residual disease 
(MRD) (1.65%) were observed. Bone marrow immunophenotyping 
performed on November 3, 2014, showed a significant increase in 
the percentage of a blast to 10%, with the evolution of the phenotype 
and a new leukemia aberrant immunophenotype (LAIP) present, that 
is, cytoplasmic myeloperoxidase (MPO)-positive blasts. The highest 
frequency of LAIP was 5.96%.
Because of the persistent weakness of the lower limbs, magnetic 
resonance imaging (MRI) of the brain was performed. Numerous foci 
in the cranial bones were observed, with no additional information 
about the nature of the lesions. The patient died in November 2014.
Case report 2
A 50-year-old male was referred to the outpatient clinic in January 
2017 due to anemia (Hgb – 10.4 g/dL), thrombocytopenia (PLT 
– 61 G/L), and splenomegaly (22 cm spleen and 21 cm liver 
in the abdominal scan). White blood cells (WBC) was normal 
(4.68 G/L). The patient reported progressive aversion to exercise 
and periodic subfebrile symptoms, weight loss over 20 kg in 
8 months. The patient was hypertensive, with no other concomitant 
diseases. Triple-negative PMF (JAK2V617F, CALR, and MPL) 
with complex karyotype 46,XY,t(11;22)(p15;q13)[4]/46,XY,t(11;22)
(p15:q13),t(12;22)(q24.3;q11.2)[12]/46,XY,i(9)(q10)[3]/46,XY 
was diagnosed [1]. Trepanobiopsy showed typical features of the 
myeloproliferative syndrome (prefibrotic myelofibrosis). International 
Prognostic Scoring System (IPSS) score was intermediate (2), The 
Dynamic Prognostic Scoring System (DIPSS) score was 2, and 
DIPSS-plus score was 3.
The patient was eligible for the ruxolitinib therapy. The treatment 
was initiated at 5 mg bid, and after 2 months, the dose was 
increased to 10 mg bid. Initially, an improvement in the patient’s 
general condition was reported with a decrease in the severity of 
general symptoms, a distinct reduction in the spleen size and an 
increase in PLT count to 137 G/L were observed. Unfortunately, 
3 months after the initiation of the ruxolitinib therapy, the patient’s 
condition was suddenly worsened. Sweats, weakness, and bone 
Table I. List of published cases of MPN transformation to ALL
No. Authors [ref.] Primary diagnosis Secondary diagnosis Time to transformation
1 Camós et al. [39] PV B-ALL 10 years
2 Suzuki  et al. [40] PV T-ALL 12 years
3 Hilal and Conley [41] ET B-ALL >20 years
4 Woronzoff-Dashkoff and Litz [42] ET ALL Unknown
5 Ohanian et al. [1] Post-PV
PMF
B-ALL 3 years
6 Alhuraiji et al. [43] ET/PMF B-ALL 11 years
7 Dunphy et al. [44] MF ALL 3 months
8 Bacher et al. [45] MPD Pre-T-ALL 18 months
9 Kim et al. [46] CMPD Biphenotypic leukemia Unknown
10 JabbarAl-Obaidi et al. [47] CMPD B-ALL 6 weeks
11 Duployez et al. [48] MPN ALL 12 months
ALL – acute lymphoblastic leukemia; B-ALL – acute B-cell lymphoblastic leukemia; T-ALL – acute T-cell lymphoblastic leukemia; pre-T-ALL – acute pre-T cell lymphoblastic leukemia; PV – 
polycythemia vera; ET – essential thrombocythemia; PMF – primary myelofibrosis; MF – myelofibrosis; CMPD – chronic myeloproliferative syndrome; MPN – myeloproliferative neoplasm
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aches returned. In complete blood count (CBC), leukocytosis 
(20 G/L), anemia (Hgb – 8.3 g/dL), and thrombocytopenia 
(PLT < 20 G/L) were observed with hyperuricemia (10.5 mg/dL) and 
increased LDH (1393 U/L) in the biochemical workup. The progression 
of hepatosplenomegaly was observed in ultrasound scan (April 
2017). The patient was not eligible for the ruxolitinib therapy. In a 
myelogram, dyserthropoiesis and dysgranulopoiesis were observed. 
Lymphoblasts constituted 71% of bone marrow cells. ALL was 
confirmed by immunophenotyping showing 68% of CD45- CD19+ 
CD34-CD117- HLA-DR+ CD24+ CD10+ TdT+ CD38+ cyCD79a+ 
cyCD22+ CD9+ CD21- CD33- CD22+ CD20-+ lymphoblasts (Fig. 2).
Between May and July 2017, the patient underwent rituximab, 
cyclophosphamide, vincristine, adriamycin and dexamethasone 
(R-hyperCVAD) chemotherapy, with a decrease in spleen size from 
26 to 22 cm and a decrease in lymphoblast count to 0.2% with 
positive MRD. In September 2017, the patient had an unknown 
donor undergoing allogeneic hematopoietic stem cell transplantation 
(allo-HSCT). However, hematopoietic lineages were not regenerated 
in the bone marrow, and hepatosplenomegaly was shown in a follow-
up abdominal scan. The myelogram performed on October 9, 2017 
revealed 15% myeloblasts and 19% myeloid blasts CD45dim+CD34- 
CD117+ MPO- CD33+ CD13+ CD19- CD20- CD38+ CD15+ CD71+ 
CD10- CD9- HLA-DR-+ (Fig. 3).
In mid-October, an analysis of post-transplant chimerism revealed 
Fig. 1. Cytometric evaluation of the first patient’s bone marrow suggesting MPAL
A – subpopulations of bone marrow cells in the FSC/SSC plot: blasts (red), lymphocytes (green), granulocytic cells (blue), and erythroblasts (yellow); B – CD45 vs SSC; C – CD34 vs  CD13; 
D – cyCD3 vs MPO; E – CD7 vs CD2; and F – cyCD3 vs CD33
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90.85% of the autologous cells in the sample. In the follow-up 
in the outpatient clinic performed at the end of the same month, 
pancytopenia was observed: WBC – 0.47 G/L, PLT – 6 G/L, Hgb 
– 6.5 g/dL, neutropenia – 0.07 G/L, lymphocytopenia – 0.16 G/L 
with CRP – 27.8 mg/L, LDH – 426 U/L, and serum cyclosporine 
concentration 70.2 ng/mL. In CBC performed at the end of 
October, 53% of myeloblasts and 21% of mature lymphocytes were 
observed. Immunophenotyping performed on 26 October 2017, 32% 
myeloblasts were found. Transformation into AML was diagnosed. 
The last contact with the patient was in October 2017.
Discussion
AML is the most commonly reported subtype of acute leukemia in the 
course of Ph-neg MPN. According to the literature, the transformation 
of Ph-neg MPN into ALL is a very rare phenomenon; no reports 
were found on the development of MPAL in the course of Ph-neg 
MPN. Similarly, no cases of the transformation of Ph-neg MPN to 
ALL with lineage switch to AML after the therapy were described. In 
contrast to Ph-neg MPN, the lymphoblastic crisis is more common 
Fig. 2. Cytometric evaluation of the second patient’s bone marrow suggesting B-cell precursor acute lymphoblastic leukemia
A – subpopulations of bone marrow cells in the FSC/SSC plot: B lymphoblasts (red), lymphocytes (green), granulocytic cells (blue), monocytes (purple), and myeloblasts (burgundy); B – 
CD45 vs SSC B CD45- lymphoblasts; C – cyCD22 vs CD10; D – CD20 vs CD19; E – CD19 vs CD117; and F – CD66c vs CD19
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in the course of chronic myeloid leukemia (CML) [8]. For example, 
in a study of 31 patients with CML in the blast crisis (BC), 24 
patients had myeloblastic and 7 had lymphoblastic disease [9]. CML 
transformation into biphenotypic leukemia/MPAL [10, 11, 12] and with 
phenotype switch [13] were also reported.
There are two main theories explaining the development of MPAL 
and leukemia with lineage switch after the therapy. According to one 
of them, hematopoietic progenitor cells have multilineage potential. 
The multilineage potential is preserved if the leukemia transformation 
occurs at this stage. According to the second hypothesis, the 
lineage switch is caused by the oncogenic reprogramming of the 
cell [14, 15, 16]. Normal, multipotent hematopoietic stem cells 
differentiate into myeloid, B or T-lymphoid cells in a complex, gradual 
maturation process that is influenced by many transcription factors. 
It depends on their levels, relative time of expression, and mutual 
interactions, both synergistic and antagonistic [17, 18]. It was shown 
that B-lineage development is dependent on a high expression of 
Pax-5 transcription factor, and that the inhibition of Pax-5 by c/EBP 
alpha induces myeloid or mixed phenotype in common lymphoid 
progenitor cells [19, 20]. C/EBPalpha is a decisive factor for myeloid 
differentiation. However, notch signaling is required to promote the 
proliferation of T-cell progenitors [21].
Diagnostics in MPAL leukemias is challenging. Initially, all 
leukemias expressing both lymphoid and myeloid markers were 
called biphenotypic [22]. However, as flow cytometry developed, 
increasingly more leukemias were shown to express antigens from 
two different lineages [23]. The first diagnostic criteria of biphenotypic 
leukemia were gathered in the EGIL classification [3] created in 
1995. This classification was based on the immunophenotype. It 
should be noted that biphenotypic leukemia should not be diagnosed 
in patients with immunophenotype changes observed during the 
induction therapy [24, 25]. The second classification is the WHO 
2016 classification of myeloid neoplasms and acute leukemias [4]. 
All acute leukemias of undetermined lineage, that is, leukemias 
characterized by the presence of more than one cell lineage or 
the expression of antigens typical for more than one lineage or the 
absence of antigens characteristic of any lineage, are classified into 
one group called MPAL. The following subtypes are distinguished: 
(1) acute undifferentiated leukemia, (2) MPAL with t(9; 22)(q34.1; 
q11.2); BCR-ABL1, (3) MPAL with t(v; 11q23.3); with KMT2A 
rearrangements, (4) B/myeloid MPAL NOS, and (5) T/myeloid MPAL, 
NOS. It is worth noting that the WHO classification does not only 
focus on the immunophenotype of blast cells but also highlights the 
importance of specific genetic aberrations.
The prognosis of MPAL is very unfavorable, as these leukemias 
are often highly resistant to the therapy. It might be related to a 
high incidence of specific chromosomal aberrations, including the 
most commonly described t(9; 22)(q34; q11.2) (Ph chromosome, 
Ph-positive) and MLL rearrangement [2, 26]. According to the 
latest reports, mutations associated with adverse prognosis are 
Fig. 3. Cytometric evaluation of the second patient’s bone marrow suggesting acute myeloid leukemia
A – subpopulations of bone marrow cells in the FSC/SSC plot: myeloblasts (red), lymphocytes (green), granulocytic cells (blue), monocytes (purple), and erythroblasts (yellow); 
B – CD45 vs SSC CD45dim + myeloblasts; C – CD10 vs CD19; and D – HLA-DR vs CD117
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often observed in MPAL [5]. Another challenge is the choice of 
treatment regimen – whether MPAL patients should be treated 
according to AML, ALL, or a combination protocol [27, 28, 29]. 
The low number of patients, diagnostic difficulties, and the lack 
of prospective clinical trials make it difficult to establish uniform, 
reliable therapeutic protocols. In 2018, Maruffi et al. [30] published 
the results of a meta-analysis of 1351 patients with MPAL (children 
and adults). The protocols used in the treatment of ALL and AML 
as well as “hybrid” regimens (containing drugs used in both) were 
compared. The incidence of complete remission (CR) was lower in 
patients treated with AML regiments compared to the group treated 
with ALL regimens. In addition, in the long-term survival analysis, 
the efficacy of ALL regimens was at least equivalent to the efficacy 
of more toxic AML regimens [30]. In patients with MPAL, the early 
evaluation of the Ph chromosome is important for the treatment 
decisions [27]. Ph-positive MPAL is usually characterized by 
a combination of B-lymphocytic and myeloid markers and 
accounts for approximately 25% of all MPAL cases [31]. Early 
administration of tyrosine kinase inhibitors is extremely important 
in this patient population, as it may improve the outcome [32, 33]. 
Allo-HSCT is indicated in all young patients without significant 
comorbidities, who achieved CR after induction chemotherapy. 
In recent retrospective studies, encouraging long-term results of 
allo-HSCT in MPAL patients in the first complete CR1 remission 
have been recently shown [34, 35, 36]. In older MPAL patients, 
hypomethylating drugs appear to be a good alternative, as shown 
by Lee et al. [37].
There are no standards for the management of patients with acute 
leukemia with lineage switch or with MPAL. The recommendations 
published by Gerr et al. [38] suggest that these patients should be 
treated according to the immunophenotype.
Conclusions
We present two very rare cases of acute leukemia (MPAL and ALL 
with lineage switch) with unfavorable prognosis in patients previously 
diagnosed as Ph-negative MPN. Because there is a lack of prospective 
controlled clinical trials needed to establish treatment standards, we 
believe that all such cases should be reported. There is a chance that 
in the future, the development of molecular diagnostics and targeted 
therapies will improve the treatment outcomes in this population.
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